Citigroup Lowers Establishment Labs (NASDAQ:ESTA) Price Target to $74.00

Establishment Labs (NASDAQ:ESTA) had its price objective cut by equities researchers at Citigroup from $81.00 to $74.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target indicates a potential upside of 16.35% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. JPMorgan Chase & Co. lifted their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wall Street Zen raised shares of Establishment Labs from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Needham & Company LLC upped their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Stephens raised their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $86.86.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $63.60 on Wednesday. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The firm’s 50-day moving average price is $70.36 and its two-hundred day moving average price is $60.25. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31. The stock has a market capitalization of $1.86 billion, a P/E ratio of -36.55 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.19) earnings per share. As a group, sell-side analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Several large investors have recently bought and sold shares of ESTA. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs during the 4th quarter worth about $47,000. Quarry LP bought a new position in shares of Establishment Labs in the third quarter valued at approximately $34,000. State of Wyoming acquired a new position in shares of Establishment Labs during the third quarter valued at approximately $71,000. MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the fourth quarter valued at approximately $146,000. Finally, Osaic Holdings Inc. raised its holdings in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.